NEU.AX - Neuren Pharmaceuticals Limited
| Previous close | 0.9700 |
| Open | 1.0000 |
| Bid | 0.9950 x 0 |
| Ask | 1.0000 x 0 |
| Day's range | 1.0000 - 1.0550 |
| 52-week range | 0.9650 - 3.0400 |
| Volume | 49,008 |
| Avg. volume | 199,570 |
| Market cap | 102.668M |
| Beta (5Y monthly) | 0.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1080 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.28 |
- Business Wire
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder. Upon FDA approval of a product with RPD designation, the sponsor may be eligible to receive a Priority Review Voucher, which can be used to obtain FDA review of a New Drug Application for another product in an expedited period of six months.
- Simply Wall St.
If You Had Bought Neuren Pharmaceuticals (ASX:NEU) Stock A Year Ago, You Could Pocket A 113% Gain Today
Unless you borrow money to invest, the potential losses are limited. But when you pick a company that is really...
- Simply Wall St.
Does Neuren Pharmaceuticals's (ASX:NEU) Share Price Gain of 43% Match Its Business Performance?
By buying an index fund, you can roughly match the market return with ease. But if you pick the right individual...
- Simply Wall St.
How Many Neuren Pharmaceuticals Limited (ASX:NEU) Shares Did Insiders Buy, In The Last Year?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- Simply Wall St.
What Kind Of Shareholder Appears On The Neuren Pharmaceuticals Limited's (ASX:NEU) Shareholder Register?
Every investor in Neuren Pharmaceuticals Limited (ASX:NEU) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller com...
